Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Loxo Oncology at Lilly presented updated clinical data from the Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent Bruton's tyrosine kinase inhibitor, at the ASH Annual Meeting. The trial enrolled 618 patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Key findings include an overall response rate (ORR) of 68% in CLL/SLL patients, and a durable median progression-free survival (PFS) not reached. The safety profile was favorable, with most adverse events being mild. Lilly aims to advance pirtobrutinib through additional Phase 3 studies.
Eli Lilly and Regor Therapeutics have formed a multi-year collaboration to develop new therapies for metabolic disorders. Lilly will license specific Regor intellectual property and handle clinical development globally, except in China, Macau, Hong Kong, and Taiwan. Regor will receive an upfront payment of up to $50 million and could earn up to $1.5 billion based on development milestones. This collaboration aims to enhance treatment options for patients with obesity and diabetes without altering Lilly's 2021 earnings guidance.
Eli Lilly and Company (NYSE: LLY) released findings from the CONFIDE Study, revealing that bowel urgency is the second most reported symptom among individuals with moderately-to-severely active ulcerative colitis (UC), affecting 47% in the past month. Notably, only 38.2% of those experiencing bowel urgency felt comfortable discussing it with healthcare providers, highlighting a significant communication gap. Despite 76.5% of respondents receiving advanced therapies, bowel urgency persisted in 46.4% of cases. The study emphasizes the need for improved patient-provider communication regarding this disruptive symptom.
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab for high-risk pediatric patients under 12 years. This allows treatment of mild to moderate COVID-19 and post-exposure prophylaxis. The decision was supported by findings from the BLAZE-1 clinical trial, showing a median symptom resolution time of 5 to 7 days. Over 700,000 patients have been treated, potentially preventing over 35,000 hospitalizations. No deaths or hospitalizations were recorded among pediatric subjects during the trial.
Eli Lilly and Company (NYSE: LLY) will hold an investment community meeting on Dec. 15, 2021, from 9 a.m. to 4 p.m. Eastern time. The meeting will include the company's initial financial guidance for 2022 and an in-depth discussion on its research and development opportunities in diabetes, immunology, neuroscience, and oncology. The event will be accessible via a live video webcast, with a replay available after the meeting.
Eli Lilly and Company (NYSE: LLY) has opened enrollment for the CHALLENGE-MIG clinical trial, the first head-to-head comparison of the anti-CGRP drugs Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant) for episodic migraine prevention in adults. The trial will assess the efficacy of monthly Emgality injections against bi-daily Nurtec tablets, focusing on migraine days reduction and quality of life. Approximately 700 adults will participate, with results anticipated to guide treatment decisions. The study highlights Lilly's commitment to advancing migraine treatment options.
Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, will engage in a fireside chat at 12:10 p.m. Eastern time. A live audio webcast of the event will be available on Lilly's Investor website, with a replay accessible for 90 days post-event.
Lilly, a global healthcare leader, focuses on creating impactful medicines and enhancing disease management.
The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) 10 mg, granting it Priority Review. This application aims to establish Jardiance as a treatment for reducing the risk of cardiovascular death and hospitalization for heart failure in adults, regardless of left ventricular ejection fraction (LVEF). In the EMPEROR-Preserved trial, Jardiance showed a 21% relative risk reduction for the primary endpoint versus placebo. If approved, it would be the first treatment proven to improve outcomes in patients with preserved ejection fraction heart failure.
Eli Lilly and Company (NYSE: LLY) has announced the winners of the inaugural Leonard Award, celebrating the 100th anniversary of insulin's discovery. Each of the five awardees will receive $20,000, totaling $100,000 in donations to Life for a Child, which aids children with type 1 diabetes in low-resource settings. The winners were chosen from over 70 submissions evaluated by an esteemed panel based on impact and feasibility. This initiative highlights Lilly's ongoing commitment to diabetes care and community support.
Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Nov. 18, 2021. Key executives, including Jacob Van Naarden, CEO of Loxo Oncology, will engage in a fireside chat at 10:30 a.m. Eastern time. Investors can access the event via a live audio webcast on the company's investor website, with a replay available for 90 days afterward. Lilly is committed to improving global health through innovative medicines and community support, continuing a century-old mission.